Use of CBD Oil in the Treatment of Posttraumatic Stress Disorder

• Status: Recruiting
• Trial end date: 2024-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The overarching objective of the proposed project is to test the clinical efficacy of CBD in the treatment of post-traumatic stress disorder using a rigorous double-blind randomized clinical trial methodology. Participants (n=150) meeting full DSM-5 criteria for post-traumatic stress disorder (PTSD) will be randomized to one of 3 treatment arms: (a) CBD -Isolate; (b) CBD-Broad Spectrum; (c) Placebo oil.

We predict that patients receiving CBD isolate or CBD Broad Spectrum will show significantly greater improvements in PTSD symptoms and functional impairment at the posttreatment, one month, and three month follow-up assessments relative to patients receiving placebo oil. Additionally, we expect that patients receiving CBD Broad Spectrum will show significantly greater improvements relative to patients receiving CBD Isolate.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Texas at Austin
• Treatments: Epidiolex

Criteria

Inclusion Criteria:

1. Meets for a current DSM-5 diagnosis of PTSD as their "primary" mental disorder

2. Age between 18 to 70

3. Fluent in English

4. Able to arrange transportation to our laboratory

5. Has access to the internet

6. Willingness to provide signed informed consent

7. Willingness to refrain from all non-study cannabis use during the study period

Exclusion Criteria:

1. History of a suicide attempt within the past 6 months

2. History of psychosis with the past 6 months

3. History of current alcohol or substance use disorder within the past month

4. Any medical problems that would preclude participating in the study

5. History of adverse reaction to CBD oil or other CBD products